CYP2C19基因多态性与氯吡格雷抵抗的研究进展

氯吡格雷是治疗急性冠脉综合征的一种经典抗血小板药物，但是临床观察到部分患者不能从氯吡格雷的治疗中获益，从而提出了氯吡格雷抵抗（CR）的问题。目前研究认为，CR受多因素影响，其中CYP2C19基因的多态性是最重要的内部因素。CYP2C19基因变异者，氯吡格雷的活性代谢产物减少，抗血小板效应减弱，不良心血管事件增加。而CYP2C19＊2和CYP2C19＊3是亚洲人最常见类型，因此，探讨CYP2C19基因的多态性对氯吡格雷疗效的影响具有临床意义。

CYP2C19 polymorphism and clopidigrel resistance： research progress

Clopidogrel is a classic antiplatelet drug for acute coronary syndrome, but clinical observation shows that some patients do not benefit from clopidogrel therapy, and the issue of clopidogrel resistance （CR） is increased. CR is related to many possible factors and CYP2C19 polymorphism is one of the most important factors. Patients with genetic variants in CYP2C19 have been found to have lower levels of the active metabolites, less antiplatelet effect and a higher rate of major adverse cardiovascular events. Moreover, CYP2C19＊2 and CYP2C19＊3 are more common in Asian populations, Thus, study of the effect of CYP2C19 polymorphism on clopidogrel therapy is of clinical significance.